Today: 17 December 2025
Subscribe
Browse Category

Healthcare Industry News 24 September 2025 - 5 November 2025

Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Company Overview & Stock Snapshot Pfizer Inc. is one of the world’s largest pharmaceutical companies, known for household-name drugs and vaccines. Headquartered in New York, Pfizer manufactures treatments across vaccines, oncology, immunology, cardiology, and more. The company gained global prominence
5 November 2025
 ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Once Sky-High Valuation Falters Amid Weight-Loss Drug Headwinds Just a year ago, Novo Nordisk – buoyed by the meteoric success of its weight-loss injection Wegovy – briefly eclipsed all other European companies in market value reuters.com. The Danish pharmaceutical giant
5 November 2025
 ·  ·  ·  ·  · 
UnitedHealth Stock Rallies After Bold Strategy Overhaul – Is 2026 a Turning Point?

UnitedHealth Stock Rallies After Bold Strategy Overhaul – Is 2026 a Turning Point?

UnitedHealth’s recent earnings and strategic shifts have drawn close market attention. The company’s Q3 2025 results beat expectations, enabling a tighter outlook. Its revenue for Q3 rose 12% to $113.2 billion unitedhealthgroup.com, with adjusted profit of $2.92 per share. That exceeded
29 October 2025
 ·  ·  ·  ·  · 
Blackstone & TPG in $18B Hologic Takeover Shock – Women’s Health Stock Skyrockets

Blackstone & TPG in $18B Hologic Takeover Shock – Women’s Health Stock Skyrockets

Deal Details and Company Background Hologic (NYSE: HOLX) is a Marlborough, MA–based medical technology firm focused on women’s health. Its products include mammography and breast biopsy systems, cervical cancer tests, surgical equipment (notably after its acquisition of Gynesonics), and lab
21 October 2025
 ·  ·  ·  ·  ·  ·  · 
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Forecast: Experts believe that within the next 2–3 years, we’ll know if Novo’s gamble pays off. Phase 3 readouts for efruxifermin are anticipated in 2026, and Novo hopes to launch the drug by late this decade if approved reuters.com. By then, the landscape
9 October 2025
 ·  ·  ·  ·  ·  · 
1 2 3 4
Go toTop